Clearside Biomedical (NASDAQ:CLSD) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $384 thousand versus the consensus estimate of $375 thousand.
Clearside Biomedical (NASDAQ:CLSD) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13). Revenue for the quarter came in at $384 thousand versus the consensus estimate of $375 thousand.